Literature DB >> 21192018

MRI-defined vascular depression: a review of the construct.

Michelle E Culang-Reinlieb1, Lauren C Johnert, Adam M Brickman, David C Steffens, Ernst Garcon, Joel R Sneed.   

Abstract

OBJECTIVE: To review the construct of MRI-defined vascular depression and to examine the substantive and methodological issues that bear on its validity as a distinct subtype of depression in late life.
DESIGN: Literature review.
RESULTS: We identified three areas that are critical to establishing the validity of MRI-defined vascular depression: (1) understanding and delineating the relationship between MRI hyperintensities, executive dysfunction, and antidepressant treatment outcome; (2) understanding the relationship between, and establishing the validity of, qualitative and quantitative approaches to the measurement of MRI hyperintensities (the primary feature of the proposed subtype); (3) establishing the clinical presentation and course of the subtype in the context of other late-life disorders.
CONCLUSIONS: Despite considerable data supporting the validity of MRI-defined vascular depression, there are a number of critical issues that remain, including establishing a causal relationship between cerebrovascular disease and late-life depression, establishing consistent diagnostic criteria, determining the importance of lesion type and location, and understanding the course of the disorder.
Copyright © 2010 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2010        PMID: 21192018     DOI: 10.1002/gps.2668

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  14 in total

1.  Successful electroconvulsive therapy for major depression misdiagnosed as Alzheimer dementia.

Authors:  Katherine S Pier; Mimi C Briggs; Rosa M Pasculli; Charles H Kellner
Journal:  Am J Geriatr Psychiatry       Date:  2012-10       Impact factor: 4.105

Review 2.  Depression in cognitive impairment.

Authors:  Laurel D Pellegrino; Matthew E Peters; Constantine G Lyketsos; Christopher M Marano
Journal:  Curr Psychiatry Rep       Date:  2013-09       Impact factor: 5.285

3.  The nuances of cognition and depression in older adults: the need for a comprehensive assessment.

Authors:  Patrick J Brown; Joel R Sneed; Bret R Rutherford; D P Devanand; Steven P Roose
Journal:  Int J Geriatr Psychiatry       Date:  2013-10-03       Impact factor: 3.485

Review 4.  Angiotensin II AT(1) receptor blockers as treatments for inflammatory brain disorders.

Authors:  Juan M Saavedra
Journal:  Clin Sci (Lond)       Date:  2012-11       Impact factor: 6.124

Review 5.  Translational application of neuroimaging in major depressive disorder: a review of psychoradiological studies.

Authors:  Ziqi Chen; Xiaoqi Huang; Qiyong Gong; Bharat B Biswal
Journal:  Front Med       Date:  2021-01-29       Impact factor: 4.592

Review 6.  The enigma of vascular depression in old age: a critical update.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2022-06-15       Impact factor: 3.850

7.  Depressive symptoms, symptom dimensions, and white matter lesion volume in older adults: a longitudinal study.

Authors:  Joshua W Kirton; Susan M Resnick; Christos Davatzikos; Michael A Kraut; Vonetta M Dotson
Journal:  Am J Geriatr Psychiatry       Date:  2013-10-11       Impact factor: 4.105

8.  [Neurobiological subtypes of geriatric depression. Their importance for diagnosis and treatment].

Authors:  M A Rapp
Journal:  Z Gerontol Geriatr       Date:  2013-02       Impact factor: 1.281

Review 9.  What are the causes of late-life depression?

Authors:  Rehan Aziz; David C Steffens
Journal:  Psychiatr Clin North Am       Date:  2013-10-06

10.  Circulating biosignatures of late-life depression (LLD): Towards a comprehensive, data-driven approach to understanding LLD pathophysiology.

Authors:  Breno Satler Diniz; Chien-Wei Lin; Etienne Sibille; George Tseng; Francis Lotrich; Howard J Aizenstein; Charles F Reynolds; Meryl A Butters
Journal:  J Psychiatr Res       Date:  2016-07-11       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.